News and Trends 23 Sep 2019
FDA Greenlights First Oral Version of Novo Nordisk’s Type 2 Diabetes Drug
The first oral drug for type 2 diabetes belonging to the class of GLP-1 agonists, developed by Novo Nordisk, has got the go-ahead from the FDA. The Danish company is known for its blockbuster injectable drug in the same class — liraglutide — that is now one of the most highly prescribed drugs in the […]